Hyperpolarized MRI Tracks Liver Enzyme Activity in Fatty Liver
Researchers used a carbon-13 molecular probe to visualize declining paraoxonase activity in animal models of steatohepatitis.
Mapping Liver Enzyme Activity with Hyperpolarized MRI
A research team in Japan has developed a magnetic resonance imaging (MRI) method that tracks the activity of an essential liver enzyme in living tissue. Paraoxonase (PON) is an enzyme produced primarily in the liver that assists with lipid metabolism and helps protect cells against oxidative stress.
Investigators led by Yoichi Takakusagi at the National Institutes for Quantum Science and Technology (QST), alongside collaborators from Nippon Sanso Corporation, published the findings in the journal Sensors & Diagnostics. Their approach uses a specialized molecular probe to measure enzyme performance noninvasively.
How the Molecular Probe Amplifies the MRI Signal
The experimental imaging technique relies on a carbon-13 molecular probe that temporarily magnifies metabolic signals inside the body. The research team synthesized carbon-13-labeled mevalonolactone ([1-¹³C]MVL) to act as a target for the PON enzyme.
When the probe enters the liver, active PON converts mevalonolactone (MVL) into mevalonic acid (MVA). By comparing the signals from both molecules, researchers can calculate local enzyme activity.
Standard MRI equipment cannot easily detect these subtle biochemical reactions. To solve that problem, the team used a SpinAligner hyperpolarizer at QST to boost the probe signal by approximately 230,000 times. That amplified signal persisted long enough for a 20-second scan to capture the enzymatic reaction in mice.
Tracking Metabolic Dysfunction Progression in Preclinical Models
In mouse models fed an induction diet, liver enzyme activity dropped progressively as metabolic disease grew more severe. The investigators tested the method across stages of metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH).
MASLD is a common metabolic condition estimated to affect roughly one in three adults. The condition frequently develops without obvious early symptoms, but it can advance to fibrosis, cirrhosis, and liver cancer.
Conventional blood tests often fail to reflect actual enzyme activity inside liver tissue because local cellular conditions alter enzyme function. The hyperpolarized imaging probe detected clear declines in living tissue function that standard systemic panels might miss.
Current Evidence Boundaries and Clinical Context
This diagnostic imaging approach remains in the preclinical research phase and has undergone testing only in laboratory mice. Clinical translation requires confirming whether the probe behaves safely in humans and whether the 20-second scan window remains practical in larger bodies.
Standard medical care for fatty liver disease still relies on routine blood tests, abdominal ultrasound, transient elastography, and liver biopsies. Individuals evaluating their metabolic risk should speak with a physician about established diagnostic pathways rather than experimental imaging protocols.
Related Articles
Studying Energy Use for Personalized Weight-Loss Treatments
University of Alberta researchers are studying metabolic adaptation in whole-room calorimeters...
Read article MetabolismGuidance Outlines Eating Disorder Screening for GLP-1 Drugs
Clinical guidance in World Psychiatry outlines screening and safety practices for prescribing...
Read article MetabolismGut Bacterium Sugar Promotes Visceral Fat Burning in Early Research
A study in Cell Host & Microbe found a sugar molecule from Clostridium immunis increases...
Read article MetabolismTwo Understudied PFAS Linked to Higher Liver Cancer Risk
Blood levels of two newer PFAS compounds doubled liver cancer odds in a USC study, with the...
Read articleWant a clinician to work up your metabolic numbers?
Opt Health runs fasting insulin, A1C, a full lipid panel and 50+ other markers, then builds a treatment plan — GLP-1s included where they're appropriate — with a physician who reviews the data with you directly.
See Opt Health's metabolic program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results